Trellis Bioscience's CellSpot" technology for identification of rare human antibodies with high specificity and affinity against multiple antigen has enabled discovery of highly efficacious strain- independent antibodies to Respiratory Syncytial Virus and to Cytomegalovirus. We have now applied CellSpot to isolate two native human antibodies with broad reactivity to Group 1 and Group 2 influenza A strains respectively. Both of these antibodies have now been shown to have in vivo efficacy. In addition, we have isolated a human antibody with in vitro activity against Influenza B. We propose to advance these therapeutic candidates to IND stage, including additional neutralization studies in vitro and in vivo, manufacturing, toxicity, and PK studies. The resulting clinical candidates are expected to provide potent post-infection antiviral activity against all currently circulating strains, and effective prophylaxis against any emerging pandemic strain.

Public Health Relevance

This project will advance the development of broad spectrum therapeutic antibodies to the influenza virus HA protein. The antibodies will have the ability to protect animals and, ultimately humans, during influenza infection and will be developed as a new therapeutic agent for this disease, with the end result of this work being a fully characterized IND candidate.

Agency
National Institute of Health (NIH)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
1R44AI106077-01A1
Application #
8780477
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Krafft, Amy
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Trellis Bioscience, LLC
Department
Type
DUNS #
City
South San Francisco
State
CA
Country
United States
Zip Code
94080